Fundz

Lilly to acquire Centessa for $38/share

PRIVATEApr 17, 2026

Acquiring Company

Lilly

Acquired Company

Centessa Pharmaceuticals plc

BiotechnologyHealth CareBiotechnologyHealth CareTherapeuticsPharmaceuticalBiopharma

Description

Lilly has announced its decision to acquire Centessa Pharmaceuticals for $38 per share plus a $9 contingent value right (CVR). This strategic move aims to enhance Lilly's portfolio and expand its capabilities in innovative therapies. The acquisition aligns with Lilly's commitment to delivering groundbreaking medicines to patients.

Quick answer

Lilly is acquiring Centessa Pharmaceuticals plc, announced April 17, 2026.

How much did Lilly pay for Centessa Pharmaceuticals plc?
The deal value was not disclosed.
What does Lilly do?
Lilly unites caring with discovery to create medicines that make life better for people around the world.

Source: Fundz verified event record.

Other recent acquisitions in Therapeutics and Pharmaceutical

Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.

Who to call at Lilly, and when

When Lilly changes hands, the new owners review vendors, systems and leadership. That is when the door opens.

  • An alert the day Lilly raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Lilly, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Lilly. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Lilly

About

Lilly unites caring with discovery to create medicines that make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help more than 47 million people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges, redefining diabetes care, treating obesity and curtailing its most devastating long-term effects, advancing the fight against Alzheimer's disease, providing solutions to some of the most debilitating immune system disorders, and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit Lilly.com and Lilly.com/newsroom or follow us on Facebook, Instagram, Twitter and LinkedIn. C-LLY

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Lilly makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Predictive Intelligence
Strategic

ML-powered predictions for Lilly's next move

Learn about Strategic plan

Frequently asked

Who acquired Centessa Pharmaceuticals plc?

Centessa Pharmaceuticals plc was acquired by Lilly. The deal was reported on April 17, 2026. Lilly unites caring with discovery to create medicines that make life better for people around the world. Lilly is privately held and operates in Biotechnology.

When did Lilly acquire Centessa Pharmaceuticals plc?

Lilly's acquisition of Centessa Pharmaceuticals plc was reported on April 17, 2026. Lilly has announced its decision to acquire Centessa Pharmaceuticals for $38 per share plus a $9 contingent value right (CVR). This strategic move aims to enhance Lilly's portfolio and expand its capabilities in innovative therapies. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.

What does Centessa Pharmaceuticals plc do?

Centessa Pharmaceuticals plc is a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines for patients. It is privately held, operating in Biotechnology.

This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.